Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Acute dyskinesia, myoclonus, and akathisa in an adolescent male abusing quetiapine via nasal insufflation: a case study

  • Mathew George1Email author,
  • Maya Haasz1,
  • Alvaro Coronado1,
  • Steven Salhanick2,
  • Lindsey Korbel3 and
  • Joseph P Kitzmiller3
BMC Pediatrics201313:187

DOI: 10.1186/1471-2431-13-187

Received: 12 April 2013

Accepted: 6 November 2013

Published: 16 November 2013



Although the benefits of antipsychotic pharmacotherapy can be pronounced, many patients develop unwanted adverse effects including a variety of movement disorders. Compared with the traditional antipsychotics, the atypical antipsychotics have a decreased risk for associated movement disorders. Drug-induced movement disorders can occur, however, and the risk of adverse events can increase significantly when medications are abused.

Case presentation

We describe the case of a 13-year-old male who presented to an emergency department with acute movement disorders after nasal insufflation of crushed quetiapine. The patient was admitted and successfully treated for neuroleptic toxicity with intravenous antihistamine pharmacotherapy. His primary care provider and psychiatrist were notified of the abuse, quetiapine was discontinued, and the patient was discharged and referred to a drug and alcohol awareness and abuse program.


The abuse of quetiapine has unfortunately become more common. This unique case report of acute movement disorders following nasal insufflation of quetiapine highlights the need for heightened vigilance when prescribing quetiapine and for increased awareness and education regarding medication-abuse.


Tardive dyskinesia Medication abuse Quetiapine insufflation


Quetiapine is an atypical antipsychotic, and its indications include psychosis, mood disorders, and bipolar disorder. It is intended for oral administration with total daily doses up to 800 mg in adults. Quetiapine has good efficacy, but also has some potential for abuse (see Table 1). Routes of abuse include insufflation and intravenous entries.
Table 1

Case report of quetiapine abuse

First author


Patient demographics

Description of quetiapine abuse

Other relevant details

Fischer [1]


53-year-old male

Unknown amount, orally

Alcohol abuse

Paparrigopoulos [2]


48-year-old male

1000 mg/day orally

Alcohol/benzodiazepine dependence

Murphy [3]


29-year-old male

Unknown amount, orally

Feigned psychotic symptoms

Reeves [4]


49-year-old male

800 mg/day orally

Alcohol/benzodiazepine abuse

23-year-old male

2400 mg/day, orally

Benzodiazepine dependence

39-year-old male

800 mg/day, orally

Exaggerated bipolar symptoms

Pinta [5]


39-year-old male

600 mg/day, orally

Opiate abuse; demanded treatment with quetiapine

Morin [6]


28-year-old female

Unknown amount, insufflation

Polysubstance abuse

Waters [7]


33-year-old male

400-800 mg, intravenously

Polysubstance dependence including benzodiazepines

Hussain [8]


34-year-old female

600 mg, intravenously

Polysubstance abuse, borderline personality disorder

Quetiapine has been associated infrequently with tardive dyskinesia [911] and with acute movements disorders including myoclonus [1214], dystonia [15], parkinsonism [16] and akathisia [17]. Drug-induced movement disorders have also been associated with cases of abuse [18]; however, most subjects were either psychotic inpatients or incarcerated individuals. This case is unique in that it involves an adolescent abusing quetiapine, via nasal insufflation, in an out-patient setting.

Case presentation

A 13-year old male presented to an ED with complaints of “frequent eye blinking” and reoccurring episodes of “stiffening and abnormal movements of the hands and neck” and “flickering of the upper lips” that began 24 hours prior to his arrival. About one week prior to presenting at the ED, the patient had been discharged from a psychiatric hospital, and his discharge medications for his mood disorder (Mood Disorder Not Otherwise Specified) included quetiapine 500 milligrams (mg) by mouth (PO) daily (qd) and valproic acid (VPA) 500 mg PO at bedtime (qhs). His dosing regimen of quetiapine for the three months before that hospitalization had been 100 mg qd, and he had not previously been prescribed VPA.

The patient reported having insufflated two crushed tablets of quetaipine 500 mg on four separate occasions in the previous forty-eight hours. His desire to experience euphoria motivated him to abuse his prescription quetiapine. He reported having not taken his prescribed VPA in three days and also reported that he had not recently used any other medications, supplements, or illicit drugs. His symptoms began two hours after the last insufflation of quetiapine, the episodes of excessive eye-blinking and lip-flickering were intermittent, and the twitching of his eyelids was continuous.

At the time of presentation, the patient was fully alert and had a Glascow Coma Scale of 15. He was afebrile, tachycardic (115 beats/minute), tachypnic (18 respirations/minute), and had normal oxygen saturation without supplemental oxygen. Physical exam abnormalities included only active twitching of both upper eyelids and bilateral dilated pupils (4/5). During observation in the emergency department, the patient had two myoclonic episodes of the extremities and intense flickering of the eyelids that the patient reported were associated with him turning his head to the right. The episodes lasted about two minutes, and the patient was alert and oriented during the episodes. The patient reported feeling restless and had a constant desire to walk. Results from a 10-panel urine toxicology screen performed at admission were negative for common drugs of abuse, and lorazepam 1.5 mg intravenous (IV) was given to relax the patient. His restlessness worsened, however, and he was admitted for observation and treatment of neuroleptic toxicity. Diphenhydramine 50 mg IV was administered, and he was in stable condition within 24 hours. Quetiapine was discontinued, and the patient was discharged and referred for substance abuse evaluation and treatment. His primary care provider and psychiatrist were notified regarding the medication abuse.


We report a case of acute movement disorders in an adolescent that likely resulted from quetiapine abuse (nasal insufflation of crushed tablets). Many patients embellish or malinger to obtain quetiapine, and its abuse is not uncommon [8, 19]. Quetiapine tablets can be crushed into powder, and many abusers will either insufflate the powder or will solubilize the powder and inject it intravenously. Abusers choose these routes of administration in order to experience more rapid onset of quetiapine’s anxiolytic effects. The toxicokinetics of intranasal insufflation of quetiapine have not been fully characterized, but this route of administration undoubtedly leads to significant acute levels of quetiapine in the central nervous system. This sudden substantial exposure is likely responsible for the acute episodes of dyskinesia, myoclonus and akathisa described in this case. The movement disorders described in this case were not likely related to use of VPA because their associations with VPA are extremely rare [20] and the patient had not been exposed to VPA (half-life 9–16 hours) in several days.

Exposure to other drugs of abuse (e.g., cocaine, phencyclidine) can cause acute movement disorders; however, the urine toxicology results and the patient report do not suggest that other drugs of abuse were involved in this case report.

Per Hill’s Criteria of Causation [21], one can reasonably conclude that this patient’s dyskinesia was related to quetiapine exposure. According to Narnajo’s Adverse Drug Reaction (ADR) scale [22] for this case, the score was 6, indicating probable cause (> 9 = definite ADR, 5–8 = probable ADR, 1–4 = possible ADR 0 = doubtful ADR). The quick response to anticholinergic pharmacotherapy is also suggestive of acute neuroleptic-associated dyskinesia. Limitations of our report include a lack of serum quetiapine measurements. This report, however, highlights the need for increased prescribing vigilance and abuse-potential awareness.


Written informed consent was obtained from the patient’s legal guardian and from the patient for publication of this case report. A copy of the written consent is available for review by the Editor of this journal.



Gamma-aminobutyric acid




By mouth




At bedtime




Valproic acid


Adverse drug reaction.



The authors have no acknowledgments regarding this manuscript. There was no funding source for the writing of this manuscript.

Authors’ Affiliations

Department of Pediatrics, St. Barnabas Hospital
Department of Emergency Medicine, Beth Israel Deaconess medical center
College of Medicine, Ohio State University


  1. Fischer BA, Boggs DL: The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature. Neurosci Biobehav Rev. 2010, 34 (4): 555-558.View ArticlePubMedGoogle Scholar
  2. Paparrigopoulos T, Karaiskos D, Liappas J: Quetiapine: another drug with potential for misuse? A case report. J Clin Psychiatry. 2008, 69 (1): 162-3.View ArticlePubMedGoogle Scholar
  3. Murphy D, Bailey K, Stone M, Wirshing WC: Addictive potential of quetiapine. Am J Psychiatry. 2008, 165 (7): 918-View ArticlePubMedGoogle Scholar
  4. Reeves RR, Brister JC: Additional evidence of the abuse potential of quetiapine. South Med J. 2007, 100 (8): 834-6.View ArticlePubMedGoogle Scholar
  5. Pinta ER, Taylor RE: Quetiapine addiction?. Am J Psychiatry. 2007, 164 (1): 174-75.View ArticlePubMedGoogle Scholar
  6. Morin AK: Possible intranasal quetiapine misuse. Am J Health Syst Pharm. 2007, 64 (7): 723-5.View ArticlePubMedGoogle Scholar
  7. Waters BM, Joshi KG: Intravenous quetiapine-cocaine use (“Q-ball”). Am J Psychiatry. 2007, 164 (1): 173-4.View ArticlePubMedGoogle Scholar
  8. Hussain MZ, Waheed W, Hussain S: Intravenous quetiapine abuse. Am J Psyhicatry. 2005, 162: 1755-1756.View ArticleGoogle Scholar
  9. Rizos E, Douzenis A, Gournellis R, et al: Tardive Dyskinesia in a patient treated with quetiapine. World J Biol Psychiatry. 2009, 10: 54-57.View ArticlePubMedGoogle Scholar
  10. Ghaemi SN: Quetiapine-related tardive dyskinesia. Am J Psychiatr. 2001, 158: 1737-View ArticlePubMedGoogle Scholar
  11. Sharma V: Treatment-emergent tardive dyskinesia with quetiapine in mood disorders. J Clin Psychopharmacol. 2003, 23: 415-416.View ArticlePubMedGoogle Scholar
  12. Velayudhan L, Kirchner V: Quetiapine-induced myoclonus. Int Clin Psychopharmacol. 2005, 20 (2): 119-20.View ArticlePubMedGoogle Scholar
  13. Strachan PM, Benoff BA: Mental status change, myoclonus, electrocardiographic changes, and acute respiratory distress syndrome induced by quetiapine overdose. Pharmacotherapy. 2006, 26: 578-82.View ArticlePubMedGoogle Scholar
  14. Aggarwal A, Jiloha RC: Quetiapine induced myoclonus. Indian J Med Sci. 2008, 62: 422-3.View ArticlePubMedGoogle Scholar
  15. Desarkar P, Sinha VK: Quetiapine-induced acute dystonia and akathisia. Aust N Z J Psychiatry. 2006, 40: 607-8.View ArticlePubMedGoogle Scholar
  16. Bharadwaj R, Grover S: Parkinsonism and akathisia with quetiapine: three case reports. J Clin Psychiatry. 2008, 69: 1189-91.View ArticlePubMedGoogle Scholar
  17. Shah R, Grover S, Maheshwari U, Kate N, Malhotra N: Acute akathisia with quetiapine: a case report and review of the literature. Indian J Pharmacol. 2010, 42: 416-7.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Sansone RA, Sansone LA: Is seroquel developing an illicit reputation for misuse/abuse?. Psychiatry. 2010, 7: 13-16.Google Scholar
  19. Pierre JM, Shnayder I, Wirshing DA, et al: Intranasal quetiapine abuse. Am J Psychiatr. 2004, 161: 1781-View ArticleGoogle Scholar
  20. Silver M, Factor SA: Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia. Parkinsonism Relat D. 2013, 19 (8): 758-60.View ArticleGoogle Scholar
  21. Austin Bradford H: The environment and disease: association or causation?. Proc R Soc Med. 1965, 58: 295-300.Google Scholar
  22. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245.View ArticlePubMedGoogle Scholar
  23. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:


© George et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.